Experimental pharmacokinetics of a new antiparkinsonian drug ADK-1113

The pharmacokinetics of a new antiparkinsonian drug ADK-1113 after single intravenous and intragastric administrations in mice at doses of 10 and 20 mg/kg was studied. The absolute bioavailability was 10.1–16.3 % that indicates on potential possibility of preparing a dosage form for oral administrat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Фармакокинетика и Фармакодинамика 2024-06 (1), p.27-31
Hauptverfasser:	Kravtsova, O. Yu, Dvoryaninov, D. A., Kolyvanov, G. B., Litvin, A. A., Gribakina, O. G., Zherdev, V. P.
Format:	Artikel
Sprache:	eng ; rus
Schlagworte:	absolute bioavailability antiparkinsonian drug (adk-1113) preclinical pharmacokinetics tandem-hplc-mass spectrometry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The pharmacokinetics of a new antiparkinsonian drug ADK-1113 after single intravenous and intragastric administrations in mice at doses of 10 and 20 mg/kg was studied. The absolute bioavailability was 10.1–16.3 % that indicates on potential possibility of preparing a dosage form for oral administration.
ISSN:	2587-7836 2686-8830
DOI:	10.37489/2587-7836-2024-1-27-31